In the assessment of 12-month price targets, analysts unveil insights for Charles River, presenting an average target of $213.12, a high estimate of $265.00, and a low estimate of $175.00. This ...

By Puyaan Singh Feb 18 (Reuters) - Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug ...

Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results , but sales were flat year on year at $1.03 billion. Its non-GAAP profit of $3.12 per share was 24.6% above ...

Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA ...

Integration of SOLVE Market Data and Predictive Pricing enhances transparency and workflow efficiency for fixed income desks SOLVE, the leading provider of pre-trade data and predictive pricing for ...

Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles River Investment Management ...